A powerful analytic tool, 3D Net Perfusion enables clinicians to gain clearer comprehension of MRI scans, improving the accuracy of diagnosis and assessment of treatment efficacy. It is also an innovative way of visualizing and measuring the blood supply to cancers--a crucial factor in tumor growth.
The software is the result of pioneering trials at the ICR led by Prof. Martin Leach, David Collins, and James d'Arcy, and is currently used in 10 research centers. Scientists from the ICR continue to work with Biotronics3D software developers to further enhance the product. Paul Carnochan, senior business development manager at the ICR, believes the partnership could have broader implications and stated, "London has an abundance of research capabilities and commercial expertise in the field of medical imaging, and we believe that collaborations like this one can be the key to raising London's profile as a major biotech hub.”
Harry Hatzakis, CEO of Biotronics 3D, commented, "Innovation carries risks and in fast moving markets such as global diagnostics it is important to leverage skills that exist outside the company through partnerships such as ours with the ICR.”
The Institute of Cancer Research (ICR) is one of Europe's leading cancer research centers with expert scientists working on cutting-edge research. In 2009, the ICR marks its 100 years of groundbreaking research into cancer prevention, diagnosis, and treatment.
Biotronics3D develops and markets software applications for the diagnostic imaging industry. The company provides software technologies to improve healthcare by better extracting diagnostic data and transforming it into usable information available at the point-of-care. Biotronics3D, Ltd. is an EN ISO 13485:2003-certified company and its flagship product, 3Dnet Suite received FDA 510K market clearance, and it is CE marked.
Related Links:
Biotronics3D
The Institute of Cancer Research
